Today: 13 April 2026
Subscribe
Browse Category

NYSE:ABT 25 January 2026 - 6 April 2026

SCHD Draws Fresh Attention After New Dividend and 2026 Reconstitution

SCHD Draws Fresh Attention After New Dividend and 2026 Reconstitution

Schwab U.S. Dividend Equity ETF paid a $0.2569 per-share dividend for March, up 3.3% from last year, and finished a major reshuffle in its annual index reset. SCHD drew $4 billion in Q1 inflows as U.S. dividend funds saw their strongest start since 2020. The fund now holds 104 stocks, with Chevron and ConocoPhillips still its largest positions. Health care and tech exposure rose, while energy and materials fell.
6 April 2026
···········
SCHD ETF Rebalance Adds Abbott, UnitedHealth as Dividend Fund Inflows Hit 4-Year High

SCHD ETF Rebalance Adds Abbott, UnitedHealth as Dividend Fund Inflows Hit 4-Year High

Schwab’s U.S. Dividend Equity ETF (SCHD) increased health care holdings to 18.5% in its annual rebalance, adding Abbott Laboratories and UnitedHealth Group near the top at about 3.8% each. SCHD attracted $4 billion in Q1 as U.S. dividend funds pulled in $24.1 billion, the highest first-quarter inflow in four years. SCHD closed at $30.48 Monday, up 0.13%.
30 March 2026
············
Abbott (ABT) stock slips on FDA warning letter over FreeStyle Libre testing; dates to watch

Abbott (ABT) stock slips on FDA warning letter over FreeStyle Libre testing; dates to watch

Abbott Laboratories shares fell 0.6% to $108.77 after the FDA issued a warning letter over quality-control lapses in its FreeStyle Libre glucose monitors. The FDA said Abbott released devices without required accuracy tests and failed to ensure specs were met by third-party manufacturers. Abbott has 15 business days to respond. Shares had dropped as much as 2.9% earlier in the session.
3 February 2026
·
Abbott (ABT) stock price steadies after Barclays trims target; Exact Sciences vote is next key date

Abbott (ABT) stock price steadies after Barclays trims target; Exact Sciences vote is next key date

Abbott Laboratories shares edged up 0.1% to $109.43 after Barclays cut its price target to $142 but kept an Overweight rating. Nutrition sales fell 8.9% last quarter, and diagnostics dropped 2.5%. Exact Sciences shareholders will vote February 20 on Abbott’s planned $23 billion takeover. The deal is expected to close in the second quarter of 2026.
2 February 2026
···
Abbott stock price today: ABT slips after Barclays cuts target as Wall Street resets expectations

Abbott stock price today: ABT slips after Barclays cuts target as Wall Street resets expectations

Abbott shares slipped 0.3% to $109.00 after Barclays cut its price target to $142 from $169, citing ongoing pressure in nutrition and diagnostics. About 6.1 million shares traded as investors awaited updates from medical meetings and the Feb. 13 dividend. The stock has struggled since missing revenue estimates and warning of slower nutrition growth in late January.
2 February 2026
·
Abbott stock price rebounds 3% after Friday rally as analysts cut targets; what’s next for ABT

Abbott stock price rebounds 3% after Friday rally as analysts cut targets; what’s next for ABT

Abbott shares closed Friday up 3.03% at $109.30, rebounding after post-earnings losses earlier in the week. Brokerages lowered price targets, citing nutrition segment challenges and a cautious outlook for early 2026. Investors are watching for updates on the Exact Sciences acquisition, expected to close in the second quarter. The S&P 500 and Dow both fell on the day.
1 February 2026
·
Abbott Laboratories stock price: ABT ends Friday up 3% — what investors watch next week

Abbott Laboratories stock price: ABT ends Friday up 3% — what investors watch next week

Abbott Laboratories shares closed up 3% at $109.30 Friday after trading between $105.72 and $109.47. CEO Robert B. Ford bought 18,800 shares on January 23 for about $2 million. The company forecast 2026 organic sales growth of 6.5%–7.5% and reaffirmed plans to acquire Exact Sciences in Q2. Abbott’s Q1 earnings and nutrition outlook remain under pressure after missing revenue estimates.
31 January 2026
·
Abbott stock rebounds as Exact Sciences vote nears after broker upgrade

Abbott stock rebounds as Exact Sciences vote nears after broker upgrade

Abbott Laboratories shares rose 2.6% to $108.89 Friday after missing revenue targets and guiding first-quarter adjusted EPS below analyst estimates. Freedom Capital Markets upgraded the stock to “buy” but cut its price target. Abbott expects to close its $23 billion Exact Sciences acquisition by Q2 2026. Exact Sciences shareholders will vote on the merger Feb. 20.
30 January 2026
···
Boston Scientific stock snaps a 4-day run — what to watch before Feb. 4 earnings

Boston Scientific stock snaps a 4-day run — what to watch before Feb. 4 earnings

Boston Scientific shares fell 1.6% to $92.33 Thursday, ending a four-day rally on heavy volume after the company completed its acquisition of Nalu Medical. The stock underperformed sector peers as investors awaited fourth-quarter results due Feb. 4 and looked for updates on recent deal activity, including the $14.5 billion Penumbra purchase.
30 January 2026
······
Abbott stock price steadies near a 52-week low as upgrade talk meets nutrition worries

Abbott stock price steadies near a 52-week low as upgrade talk meets nutrition worries

Abbott Laboratories shares rose 0.3% to $106.34 Thursday after a broker upgrade, following sharp losses from missed revenue and a cautious outlook last week. The stock touched a 52-week low of $105.27. Abbott plans to acquire Exact Sciences for $105 per share, with a shareholder vote set for Feb. 20. The company declared a $0.63 quarterly dividend, payable Feb. 13.
29 January 2026
··
Abbott stock slides after CEO’s $2 million buy hits SEC filing — what investors watch next

Abbott stock slides after CEO’s $2 million buy hits SEC filing — what investors watch next

Abbott shares fell 2.1% to $106.05 Wednesday after CEO Robert Ford bought about $2 million in stock through a family trust, according to an SEC filing. The stock has dropped 12% in five sessions following a disappointing earnings report and a price target cut by Argus. Investors are watching for updates at major medical conferences starting Jan. 29 in New Orleans.
29 January 2026
·
Abbott Laboratories stock price slides as Argus cuts target and CEO Ford discloses share buy

Abbott Laboratories stock price slides as Argus cuts target and CEO Ford discloses share buy

Abbott Laboratories shares fell about 2% to $106.12 Wednesday after Argus cut its price target to $140, following last week’s earnings warning. CEO Robert Ford bought 18,800 shares on Jan. 23 at an average $107.13, according to an SEC filing. The broader healthcare sector slipped ahead of the Federal Reserve’s rate decision. Abbott cited weak nutrition and diagnostics sales and higher costs for its recent profit miss.
28 January 2026
·
ISRG stock slips after FDA clears da Vinci 5 for heart procedures; TD Cowen starts at Buy

ISRG stock slips after FDA clears da Vinci 5 for heart procedures; TD Cowen starts at Buy

Intuitive Surgical shares fell 0.7% to $525.09 Tuesday after the FDA cleared its da Vinci 5 robot for select cardiac procedures. The S&P 500 ETF rose 0.5% and QQQ gained 0.9%. TD Cowen initiated coverage with a Buy rating and $660 target, citing potential for expanded hospital adoption. Intuitive forecasts 13–15% da Vinci procedure growth in 2026, with a 1.2% revenue hit from tariffs.
27 January 2026
····
Abbott stock price today: ABT slips as CEO buy hits SEC filing after volatile week

Abbott stock price today: ABT slips as CEO buy hits SEC filing after volatile week

Abbott Laboratories shares fell 1.2% to $107.49 by midday Tuesday after CEO Robert Ford disclosed buying 18,800 shares at an average price of $107.13. The drop followed a weak quarterly outlook and missed revenue targets, with investors watching ongoing challenges in Abbott’s nutrition segment. Health-care stocks broadly declined after a proposed near-flat Medicare Advantage payment rate for 2027.
27 January 2026
·
Abbott stock ticks higher after CEO Robert Ford buys $2 million of ABT shares

Abbott stock ticks higher after CEO Robert Ford buys $2 million of ABT shares

Abbott Laboratories shares rose about 1% Monday after CEO Robert Ford bought nearly $2 million in stock, acquiring 18,800 shares at an average $107.13 each. The stock traded at $108.49 midday. Ford now holds 253,305 shares directly and 216,203 through a trust. The purchase follows last week’s earnings report and guidance update, with Q4 adjusted earnings at $1.50 per share on $11.459 billion in sales.
26 January 2026
·
Abbott Laboratories stock faces a Monday test as ABT hovers near a 52-week low

Abbott Laboratories stock faces a Monday test as ABT hovers near a 52-week low

Abbott shares fell 10.04% Thursday, their sharpest drop since 2002, closing Friday at $107.42. Analysts cut price targets after the company reported Q4 adjusted EPS of $1.50 and warned of weak nutrition sales for “a couple quarters.” Volume spiked to 37.1 million shares. The company expects full-year 2026 adjusted EPS of $5.55 to $5.80 and plans to close its Exact Sciences acquisition in Q2.
25 January 2026
·
1 2 3

Stock Market Today

  • Equities Face Uncertainty as War Clouds Hover Over Markets
    April 13, 2026, 2:10 AM EDT. Indian equities experienced sharp sell-offs amid escalating conflict, with the Nifty and Sensex each falling around 3% from February 27 to March 6, the outbreak period. The markets then suffered a further drop exceeding 5% the following week. A brief pause ensued, marked by a flat trading week, before slipping again by more than 1% in the week of March 23. Investors remain cautious as geopolitical tensions continue to threaten market stability.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 13.04.2026

13 April 2026
LIVEMarkets rolling coverageStarted: April 13, 2026, 12:00 AM EDTUpdated: April 13, 2026, 2:12 AM EDT Equities Face Uncertainty as War Clouds Hover Over Markets April 13, 2026, 2:10 AM EDT. **Indian equities experienced sharp sell-offs amid escalating conflict**, with the Nifty and Sensex each falling around 3% from February 27 to March 6, the outbreak period. The markets then suffered a further drop exceeding 5% the following week. A brief pause ensued, marked by a flat trading week, before slipping again by more than 1% in the week of March 23. Investors remain cautious as geopolitical tensions continue to threaten
Bitcoin Price Today Slips After Iran Talks End Without Deal, but ETF Buyers Keep Showing Up

Bitcoin Price Today Slips After Iran Talks End Without Deal, but ETF Buyers Keep Showing Up

12 April 2026
Bitcoin fell 1.4% to $71,707 on Sunday after U.S.-Iran talks in Islamabad ended without a deal. Spot bitcoin ETFs logged net inflows last week, with BlackRock and Fidelity leading Friday’s buying. Morgan Stanley launched its MSBT fund on April 8, the first Wall Street bank to debut a bitcoin ETF. U.S. inflation data showed headline CPI up 3.3% in March, while core CPI rose 2.6%.
XRP Price Today: XRP Slips to $1.33 After Failed U.S.-Iran Talks Hit Crypto

XRP Price Today: XRP Slips to $1.33 After Failed U.S.-Iran Talks Hit Crypto

12 April 2026
XRP slipped about 1% to $1.33 on Sunday after U.S.-Iran peace talks in Islamabad ended without a deal, pressuring crypto markets. The token traded in a narrow range, with bitcoin and ether also weaker. XRP’s market cap stands at $81.7 billion, with $1.96 billion in daily volume. The token remains 63.5% below its all-time high.
Gold Price Today: Bullion Near $4,762 After Weekly Gain, but Failed Iran Talks Cloud Outlook

Gold Price Today: Bullion Near $4,762 After Weekly Gain, but Failed Iran Talks Cloud Outlook

12 April 2026
Spot gold steadied at $4,761.79 an ounce Friday after a third weekly gain, with U.S. futures at $4,787.40. The dollar posted its biggest weekly drop since January, making gold cheaper for non-U.S. buyers. U.S.-Iran talks ended without a deal, keeping geopolitical risks high. China’s central bank increased gold reserves for a 17th month, reaching 74.38 million ounces.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 12.04.2026

12 April 2026
Futu Holdings (FUTU) rose 10.2% in the past week but trades 13.4% below its January level. Shares closed at $154.50, while analysts estimate intrinsic value at $245.48. The company posted a 92.2% return over 12 months. Valuation models indicate earnings exceed risk costs, supporting long-term growth projections.
Go toTop